Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

879 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma.
Hess G, Dreyling M, Oberic L, Gine E, Zinzani PL, Linton K, Vilmar A, Jerkeman M, Chen JMH, Ohler A, Stilgenbauer S, Thieblemont C, Lambert J, Zilioli VR, Sancho JM, Jimenez-Ubieto A, Fischer L, Eyre TA, Keeping S, Park JE, Wu JJ, Nunes A, Reitan J, Wade SW, Salles G. Hess G, et al. Among authors: salles g. Leuk Lymphoma. 2024 Jan;65(1):14-25. doi: 10.1080/10428194.2023.2268228. Epub 2024 Jan 10. Leuk Lymphoma. 2024. PMID: 37840282
Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor.
Salles G, Chen JMH, Zhang I, Kerbauy F, Wu JJ, Wade SW, Nunes A, Feng C, Kloos I, Peng W, Snider JT, Maciel D, Chan K, Keeping S, Shah B. Salles G, et al. Adv Ther. 2024 May;41(5):1938-1952. doi: 10.1007/s12325-024-02822-z. Epub 2024 Mar 18. Adv Ther. 2024. PMID: 38494543 Free PMC article.
B-cell non-Hodgkin lymphomas.
Silkenstedt E, Salles G, Campo E, Dreyling M. Silkenstedt E, et al. Among authors: salles g. Lancet. 2024 May 4;403(10438):1791-1807. doi: 10.1016/S0140-6736(23)02705-8. Epub 2024 Apr 10. Lancet. 2024. PMID: 38614113 Review.
CAR T-cell therapy in large B cell lymphoma.
Boardman AP, Salles G. Boardman AP, et al. Among authors: salles g. Hematol Oncol. 2023 Jun;41 Suppl 1(Suppl 1):112-118. doi: 10.1002/hon.3153. Hematol Oncol. 2023. PMID: 37294963 Review.
Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study.
Duell J, Abrisqueta P, Andre M, Gaidano G, Gonzales-Barca E, Jurczak W, Kalakonda N, Liberati AM, Maddocks KJ, Menne T, Nagy Z, Tournilhac O, Kuffer C, Bakuli A, Amin A, Gurbanov K, Salles G. Duell J, et al. Among authors: salles g. Haematologica. 2024 Feb 1;109(2):553-566. doi: 10.3324/haematol.2023.283480. Haematologica. 2024. PMID: 37646664 Free PMC article. Clinical Trial.
Efficacy of a short sandwich protocol, methotrexate, gemcitabine, L-asparaginase and dexamethasone chemotherapy combined with radiotherapy, in localised newly diagnosed NK/T-cell lymphoma: A French retrospective study.
Chaubard S, Marouf A, Lavergne D, Lemonnier F, Rossignol J, Clavert A, Gressin R, Cartron G, Waultier-Rascalou A, Vargaftig J, Salles G, Bachy E, Ghesquières H, Tournilhac O, Chauchet A, Le Gouill S, Damaj G, Fornecker LM, Sibon D, Obéric L, Michot JM, Gaulard P, Hermine O, Couronné L, Jaccard A. Chaubard S, et al. Among authors: salles g. Br J Haematol. 2023 May;201(4):673-681. doi: 10.1111/bjh.18689. Epub 2023 Feb 17. Br J Haematol. 2023. PMID: 36799516
Conventional and novel [18F]FDG PET/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphoma.
Leithner D, Flynn JR, Devlin SM, Mauguen A, Fei T, Zeng S, Zheng J, Imber BS, Hubbeling H, Mayerhoefer ME, Bedmutha A, Luttwak E, Corona M, Dahi PB, Luna de Abia A, Landego I, Lin RJ, Palomba ML, Scordo M, Park JH, Tomas AA, Salles G, Lafontaine D, Michaud L, Shah GL, Perales MA, Shouval R, Schöder H. Leithner D, et al. Among authors: salles g. J Hematol Oncol. 2024 Apr 23;17(1):21. doi: 10.1186/s13045-024-01540-x. J Hematol Oncol. 2024. PMID: 38649972 Free PMC article.
The European Hematology Association Roadmap for European Hematology Research: a consensus document.
Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Döhner H, de Wit TD, Eichinger S, Fibbe W, Green T, de Haas F, Iolascon A, Jaffredo T, Rodeghiero F, Salles G, Schuringa JJ; EHA Roadmap for European Hematology Research. Engert A, et al. Among authors: salles g. Haematologica. 2016 Feb;101(2):115-208. doi: 10.3324/haematol.2015.136739. Epub 2016 Jan 27. Haematologica. 2016. PMID: 26819058 Free PMC article.
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
Epstein-Peterson ZD, Drill E, Aypar U, Batlevi CL, Caron P, Dogan A, Drullinsky P, Gerecitano J, Hamlin PA, Ho C, Jacob A, Joseph A, Laraque L, Matasar MJ, Moskowitz AJ, Moskowitz CH, Mullins C, Owens C, Salles G, Schöder H, Straus DJ, Younes A, Zelenetz AD, Kumar A. Epstein-Peterson ZD, et al. Among authors: salles g. Haematologica. 2024 Apr 1;109(4):1149-1162. doi: 10.3324/haematol.2023.282898. Haematologica. 2024. PMID: 37646671 Free PMC article. Clinical Trial.
Atrial arrhythmias following CAR-chimeric antigen receptor T-cell therapy: Incidence, risk factors and biomarker profile.
Shouval R, Goldman A, Flynn JR, El-Moghraby A, Rehman M, Devlin SM, Corona M, Landego I, Lin RJ, Scordo M, Raj SS, Giralt SA, Palomba ML, Dahi PB, Walji M, Salles G, Nath K, Geyer MB, Park JH, Fein JA, Kosmidou I, Shah GL, Liu JE, Perales MA, Mahmood SS. Shouval R, et al. Among authors: salles g. Br J Haematol. 2024 May 12. doi: 10.1111/bjh.19497. Online ahead of print. Br J Haematol. 2024. PMID: 38735683
879 results